Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$41.68 - $58.07 $287,592 - $400,683
6,900 Added 39.43%
24,400 $1.42 Million
Q2 2024

Aug 15, 2024

BUY
$44.58 - $66.89 $263,022 - $394,651
5,900 Added 50.86%
17,500 $799,000
Q1 2024

May 07, 2024

BUY
$41.26 - $70.48 $478,616 - $817,568
11,600 New
11,600 $767,000
Q1 2023

May 16, 2023

BUY
$41.44 - $59.32 $256,928 - $367,784
6,200 Added 95.38%
12,700 $542,000
Q4 2022

Feb 14, 2023

SELL
$39.45 - $51.77 $114,405 - $150,133
-2,900 Reduced 30.85%
6,500 $312,000
Q3 2022

Nov 14, 2022

BUY
$27.8 - $40.12 $261,320 - $377,128
9,400 New
9,400 $354,000
Q2 2022

Aug 15, 2022

SELL
$26.03 - $67.04 $356,611 - $918,448
-13,700 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$42.12 - $59.36 $1.05 Million - $1.48 Million
-24,900 Reduced 64.51%
13,700 $745,000
Q4 2021

Feb 14, 2022

BUY
$36.95 - $62.89 $1.43 Million - $2.43 Million
38,600 New
38,600 $2.26 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.48B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.